Health & Fitness
Health and Fitness
Health and Fitness
Thu, June 9, 2011Wed, June 8, 2011Tue, June 7, 2011Mon, June 6, 2011Sat, June 4, 2011Fri, June 3, 2011Thu, June 2, 2011Wed, June 1, 2011Tue, May 31, 2011Mon, May 30, 2011Fri, May 27, 2011Thu, May 26, 2011Wed, May 25, 2011Tue, May 24, 2011Mon, May 23, 2011Sun, May 22, 2011Fri, May 20, 2011Thu, May 19, 2011Wed, May 18, 2011Tue, May 17, 2011Mon, May 16, 2011Sun, May 15, 2011Fri, May 13, 2011Thu, May 12, 2011Wed, May 11, 2011Derma Sciences to Hold Conference Call Tomorrow, May 25 to Discuss 24-Week Data from Phase 2 DSC127 Trial in Diabetic Foot Ulce
Published in Health and Fitness on Tuesday, May 24th 2011 at 13:20 GMT by Market Wire
PRINCETON, N.J.--([ BUSINESS WIRE ])--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, will issue a news release announcing 24-week data from its Phase 2 trial with DSC127 in diabetic foot ulcers at 7:00 a.m. Eastern time Wednesday, May 25 and will hold a conference call to discuss those results at 11:00 a.m. Eastern time that same day.
To participate in the conference call, from the U.S. please dial (888) 563-6275 and from outside the U.S. please dial (706) 634-7417. All listeners should provide passcode 67127770. Individuals interested in listening to the live conference call via the Internet may do so by logging onto the Companya™s website, [ www.dermasciences.com ]. Slides summarizing the clinical data will be available at [ dermasciences.com/dsc127slides ].
Following the completion of the conference call, a replay will be available through June 1, 2011, and can be accessed by dialing (800) 642-1687 from the U.S. or (706) 645-9291 from outside of the U.S. All listeners should provide passcode 67127770. The webcast will also be available on the Companya™s website for 30 days.
About Derma Sciences, Inc
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace, traditional dressings, advanced wound care dressings, and pharmaceutical wound care products. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention. Derma Sciences has successfully completed a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction. For more information please visit [ www.dermasciences.com ].
